infopia Co., Ltd – Trademark Portfolio
Entity Type: 03
infopia Co., Ltd holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 13 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include OHCARE, INFOPIA, and LIPIDPRO. The owner is based in Kyunggi, 431-080.
891, Hogye-Dong, Dongan-Gu, Anyang
Kyunggi, 431-080 , KR
Showing of trademarks Trademarks
Trademark Classifications
infopia Co., Ltd's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does infopia Co., Ltd have?
infopia Co., Ltd has 21 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned, 15 cancelled.
What trademark classes does infopia Co., Ltd file in?
infopia Co., Ltd files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 35 (Advertising & Business), Class 7 (Machinery). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are infopia Co., Ltd's most well-known trademarks?
infopia Co., Ltd's registered trademark portfolio includes well-known marks such as OHCARE, INFOPIA, and LIPIDPRO. These are among 5 currently registered trademarks in the portfolio.
What is infopia Co., Ltd's trademark registration success rate?
infopia Co., Ltd has a 24% trademark registration rate, with 5 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.